In a Phase III study, neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET), interstitial lung disease occurred in two patients in the neratinib group and one patient in the placebo group, pulmonary fibrosis in one and two patients, respectively, and pneumonitis in one patient in each group (224)